Across TCGA pan-cancer cohorts, HOXA5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HOXA5 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher HOXA5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HOXA5 expression acts as an unfavorable survival marker.
SCLC, BRCA, and SARC are the cancer types where HOXA5 Mutation most reproducibly stratifies survival.